CymaBay Therapeutics (NASDAQ:CBAY) Given Neutral Rating at UBS Group theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Stock Analysts’ updated eps estimates for Wednesday, February 14th: Airbnb (NASDAQ:ABNB) had its neutral rating reiterated by analysts at Wedbush. They currently have a $160.00 price target on the stock, up from their previous price target of $150.00. Abbott Laboratories (NYSE:ABT) had its outperform rating reissued by analysts at Royal Bank of Canada. The firm […]
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates FANG, CBAY, WISH menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Wall Street kicked off the week with small moves in stocks, bonds and the dollar ahead of inflation figures that will be key to determine the scope and timing of
Seeking to rejuvenate itself after recent disappointments, Gilead Sciences Inc. proposes to bolster its liver portfolio by taking over Cymabay Therapeutics Inc. for $32.50 per share in cash, a total equity value of $4.3 billion. The arrangement brings aboard seladelpar for second-line primary biliary cholangitis (PBC) including pruritis (itch), which is under priority review by the U.S. FDA, with a decision due this year.